JaneEMinturnMDPhD

Pediatric Hematology & Oncology • Philadelphia, PA

Pediatric Neuro-Oncology

Professor of Clinical Pediatrics, Perelman School of Medicine

Join to view full profile

Dr. Minturn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Minturn's full profile

Already have an account?

Office
3501 Civic Center Blvd, ARC 1354
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104
Phone+1 215-590-2299

Fax+1 215-590-3296

Summary

Dr. Jane Minturn is a pediatric hematologist/oncologist in Philadelphia, PA and is affiliated with Children's Hospital of Philadelphia. She received her medical degree from Yale University School of Medicine and has been in practice 21 years. She specializes in pediatric neuro-oncology.

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1999 - 2002
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1996 - 1999
Yale School of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2021 - 2026
VA State Medical License 2021 - 2026
DE State Medical License 2022 - 2025
MD State Medical License 2021 - 2025
NC State Medical License 2021 - 2025
NJ State Medical License 2022 - 2025
PA State Medical License 1999 - 2024
American Board of Pediatrics Pediatric Hematology-Oncology
Join now to see all

Clinical Trials

Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
Active, not recruiting
Phase 2
Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Active, not recruiting
Early Phase 1
Roles: Contact
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma Start of enrollment: 2022 Feb 22
Recruiting
Not Applicable
Roles: Contact, Sub-Investigator
Join now to see all

Publications & Presentations

PubMed

Thirty-two-month-old with multiple duodenal webs diagnosed after failed gastrojejunostomy exchange successfully treated with combination endoscopic therapy.
Naomi E B Tjaden, Michael Acord, Jane Minturn, Myron Allukian, Petar Mamula
JPGN Reports. 2024-11-01
2 citations
Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
Daphne A Haas-Kogan, Mariam S Aboian, Jane E Minturn, Sarah E S Leary, Mohamed S Abdelbaki
Journal of Clinical Oncology. 2024-02-01
1 citations
The Impact of Proactive Gastrostomy Tube Placement on Treatment-related Outcomes in Young Children With High-grade Central Nervous System Tumors.
Chelsea Kotch, Caitlin W Elgarten, Jessica McWhorter, Cynthia Schmus, Darielle Wilhelm
Journal of Pediatric Hematology/oncology. 2023-08-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member